Phase 2 N=22 Intranasal Capsaicin Treatment for Non-Allergic Irritant Rhinitis
Nonallergic Irritant Rhinitis
Primary: Change in Total Symptom Score — -5; 2 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=155 A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® Cream, 0.1% in the Topical Treatment of Acne Vulgaris
Acne Vulgaris
Primary: Adverse Event Occurences in DFD-03 Lotion Versus Tazorac Cream Groups — 73; 81; 14; 15 Adverse Events
Phase 2 N=57 Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079)
HCV Infection
Primary: Area Under the Plasma Concentration-Time Curve From Dosing to 24 Hours Postdose (AUC0-24hr) of EBR at Steady State — 2.41; 2.79; 1.71; 3.15 µM*hr
Phase 2 N=5 Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD)
Obsessive-Compulsive Disorder
Primary: Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) — 29.00; 26.20 score on a scale — p=.20
Phase 2 N=51 A Study of E7080 in Subjects With Advanced Thyroid Cancer
Thyroid Cancer
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) — 100.0; 82.4; 52.9; 2.0 Percentage of participants
Phase 2 N=167 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
Breast Neoplasm
Primary: Objective Response Rate (ORR) — 25.8; 21.8; 23.4 percentage of participant
Phase 2 N=226 A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients
Chronic Spontaneous Urticaria
Primary: Number of Participants With at Least One Treatment Emergent Adverse Event (AE) — 190 Participants
Phase 2 N=107 A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects
Bleeding
Primary: Percent Change in Anti-Fxa Activity From Baseline to the End of Infusion (EOI) Nadir. — -94.50; -29.00; -98.00; -37.00 percent change — p=0.0275
Phase 2 N=107 Dose-finding Study to Assess the Efficacy, Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection
Non-cystic Fibrosis Bronchiectasis
Primary: Change From Baseline to Day 29 in Pseudomonas Aeruginosa (P. Aeruginosa) Density in Sputum (log10 CFUs) — 6.80; 7.67; 6.10; 6.98 log10 CFUs
Phase 2 N=51 A Phase 2a, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of IBD98-M
Colitis, Ulcerative
Primary: Remission Rate — 2; 1; 2 Participants
Phase 2 N=87 Study of Cardiovascular Disease and Obstructive Sleep Apnea
Severe Obstructive Sleep Apnea (Apnea Hypopnea Index > 30 Events/Hour) · Hypertension
Primary: Change in Muscle Sympathetic Nerve Activity Responses During Hypoxia — -0.54; -0.84; -0.71; -0.69 bursts/minute*%SaO2
Phase 2 N=131 ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Primary: Progression-Free Survival (PFS) Following Treatment With Tivantinib (ARQ 197) in Combination With Irinotecan and Cetuximab in Participants With Metastatic Colorectal…
Phase 2 N=16 Pharmacokinetics of Advantage Arrest
Dental Caries
Primary: Observed Fluoride Urinary Recovery — 1.29 mg
Phase 2 N=3 Efficacy, Tolerability and Pharmacokinetics of Subcutaneous Exendin (9-39) in Patients With Post Bariatric Hypoglycemia
Post Bariatric Hypoglycemia
Primary: Nadir Glucose — 41; 43; 39; 42 mg/dL
Phase 2 N=18 Pregabalin as Treatment for Alcohol Use Disorder
Alcohol Use Disorder
Primary: Maximum Dose of Pregabalin: — 571.4 milligrams